VIJAYA DIAGNOSTIC share price has zoomed 6% and is presently trading at Rs 839.0.
Meanwhile, the BSE HEALTHCARE index is at 40,425.9 (up 0.9%).
Among the top gainers in the BSE HEALTHCARE index today are GLAND PHARMA (up 3.8%) and ASTRAZENECA PHARMA (up 3.8%).
FORTIS HEALTHCARE (down 0.9%) and Lupin (down 0.8%) are among the top losers today.
Over the last one year, VIJAYA DIAGNOSTIC has moved up from Rs 440.6 to Rs 839.0, registering a gain of Rs 398.4 (up 90.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,485.7 to 40,425.9, registering a gain of 47.1% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 127.3%), GRANULES INDIA (up 102.8%) and SUVEN PHARMACEUTICALS (up 102.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,153.9 (up 0.5%).
The top gainers among the BSE Sensex today are Tech Mahindra (up 2.2%) and JSW Steel (up 2.0%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,176.3 (up 0.5%). Tech Mahindra and Adani Enterprises are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,782.8 to 79,153.9, registering a gain of 13,371.1 points (up 20.3%).
VIJAYA DIAGNOSTIC net profit grew 19.4% YoY to Rs 315 million for the quarter ended June 2024, compared to a profit of Rs 264 million a year ago. Net sales rose 29.1% to Rs 1,562 million during the period as against Rs 1,211 million in April-June 2023.
For the year ended March 2023, VIJAYA DIAGNOSTIC reported 23.0% decrease in net profit to Rs 852 million compared to net profit of Rs 1,107 million during FY22. Revenue of the company fell 0.7% to Rs 4,592 million during FY23.
The current Price to earnings ratio of VIJAYA DIAGNOSTIC, based on rolling 12 month earnings, stands at 69.0.
Equitymaster requests your view! Post a comment on "VIJAYA DIAGNOSTIC Gains 6%; BSE HEALTHCARE Index Up 0.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!